Detalhe da pesquisa
1.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler
; 28(10): 1526-1540, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261318
2.
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
J Med Internet Res
; 23(10): e29558, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34612826
3.
Improvement of long-term risks of cardiovascular events associated with community-based disease management in Chinese patients of the Xinjiang autonomous region of China.
BMC Public Health
; 20(1): 1034, 2020 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32600440
4.
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
J Med Internet Res
; 22(2): e16932, 2020 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32049062
5.
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Diabetes Obes Metab
; 18(10): 1045-9, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27265507
6.
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Qual Life Res
; 25(5): 1199-207, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26424170
7.
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Cardiovasc Diabetol
; 14: 11, 2015 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25633683
8.
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
J Interferon Cytokine Res
; 43(6): 246-256, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454249
9.
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Neurol Neuroimmunol Neuroinflamm
; 10(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414428
10.
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Mult Scler J Exp Transl Clin
; 9(1): 20552173231153557, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36816812
11.
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Diabetologia
; 60(6): 1159-1160, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28374067
12.
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Mult Scler J Exp Transl Clin
; 8(2): 20552173221105642, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35755007
13.
Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.
Neurol Neuroimmunol Neuroinflamm
; 9(3)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35318259
14.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
J Neurol
; 269(9): 5093-5104, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35639197
15.
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Neurol Neuroimmunol Neuroinflamm
; 9(1)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34848501
16.
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Diabetologia
; 57(12): 2599-602, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25280671
17.
Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.
Endocrinol Diabetes Metab
; 1(2): e00016, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30815552
18.
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Diabetes Care
; 38(9): 1730-5, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26180105
19.
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Diabetes Care
; 36(12): 4015-21, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24186878
20.
Molecular effects of C-Peptide in microvascular blood flow regulation.
Rev Diabet Stud
; 6(3): 159-67, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-20039005